

FLORIDA DEPARTMENT OF HEALTH IN SEMINOLE COUNTY EPIDEMIOLOGY NEWSLETTER // JUNE 2021 // ISSUE 3

#### What s Included?

PAM Awareness1
LGBTQ+ Health Disparities/Care2
Mosquito Control Awareness2, 4
Monthly Surveillance Data3
Additional Info & Resources4

#### Seminole County Highlights

Of all eligible Seminole County residents, 55% have received at least one dose of a COVID-19 vaccine.





increased human exposures to bats in Seminole County. Bats are high risk for carrying rabies. Learn how to prevent exposures to bats and rabies.

There has been

Seasonal influenza surveillance for the 2020-2021 influenza season concluded in May 2021.





COVID-19 cases are decreasing in Seminole County when compared to prior months. For more info, visit the COVID-19 dashboard.

#### Primary Amebic Meningoencephalitis (PAM) Awareness

Now that summer has arrived, Floridians and visitors will be enjoying recreational water activities, therefore leading to increased possibility of waterborne disease transmission. One of the diseases of concern is Primary Amebic Meningoencephalitis (PAM), that is contracted when water contaminated with the ameba *Naegleria fowleri* enters the nose and travels to the brain. Other amebae can cause amebic encephalitis such as acanthamoeba and *Balamuthia mandrillaris*. Symptoms are similar to bacterial meningitis and include fever, nausea, vomiting and headache and progress into stiff neck, seizures, altered metal status, hallucinations, and coma. While cases of PAM are rare, the disease is usually fatal if not treated promptly.

*Naegleria fowleri* is a free-living ameba that inhabits soil and warm freshwater environments such as lakes, rivers and hot springs. As water sources become warmer during the summer months, the chances of exposure to water contaminated with ameba increases. Ingesting this water will not result in infection, but swimming behaviors that allow water to enter one's nose are associated with infection, which include diving, jumping or submerging the head in the water.

From 1962-2019, there have been 148 cases of PAM in the United States. Of these, only 4 have survived, giving PAM a 97% fatality rate. Laboratory detection methods of *N. fowleri* include direct visualization of the organism under a microscope, polymerase chain reaction, or antigen detection of CSF, tissue, or biopsy specimens. Diagnosis has been made after the death of the patient in 75% of cases. Treatment for PAM includes miltefosine, which is commercially available.

Heathcare providers that have a patient with a suspected amebic infection are encouraged to contact The Florida Department of Health as soon as possible. Amebic encephalitis is required to be reported to the Florida Department of Health (FDOH) 24 hours a day, 7 days a week by phone upon diagnosis; however, providers may consider contacting DOH for guidance upon suspicion or laboratory test order. DOH and CDC can offer 24/7 guidance on diagnosis, treatment, and instructions on specimen collection and shipment.

For more information on PAM, please visit the CDC PAM website and the <u>FDOH PAM information page</u>. To report a case of PAM or other amebic encephalitis, call 407-665-3243 Monday-Friday from 8am-5pm and 407-665-3000, option 1, on evenings, weekends and holidays.







Three stages of Naegleria fowleri: cyst, trophozoite, flagellate (top to bottom). Image courtesy of CDC.

1

## LGBTQ+ HEALTH DISPARITIES AND CULTURALLY COMPETENT CARE

June is nationally celebrated as Pride Month, which observes the month in which many lesbian, gay, bisexual transgender, queer and other members of sexual and gender minority groups (LGBTQ+) fought for equal rights and treatment at the Stonewall Inn in New York. Although great strides have been made in the inclusion and acceptance of the LGBTQ+ community, individuals who identify as LGBTQ+ are still medically underserved and are faced with major health disparities linked to societal stigma, discrimination, and denial of their civil and human rights.

Risk of sexually transmitted diseases (STDs), cancers, cardiovascular diseases, obesity, depression, anxiety, and suicide have been found to be higher in the LGBTQ+ community,

both in adults and youth, as compared to the general population. Among LGBTQ+ youth, the CDC's 2017 Youth Risk Behavior Survey (YRBS) showed that 48% of LGBTQ+ youth have seriously considered suicide, compared to 13% in heterosexual youth. Young gay and bisexual men have disproportionately higher rates of HIV, syphilis, and other STDs compared to their heterosexual peers. Additionally, 30% of LGBTQ+ adults either do not seek healthcare services or lack a regular healthcare provider, compared to 10% in age-matched heterosexuals. Many factors play into this, including lack of coverage in insurance for hormone therapy or mental health services, associated costs due to lack of coverage, and a lack of trust and understanding in their patient-provider relationships. Many LGBTQ+ adults have expressed concern about receiving substandard care and stigmatization as a result of their sexual orientation or gender identity. This lack of communication is responsible for poor therapeutic alliance, lack of appropriate health education, inadequate screening for communicable diseases, and inadequate interventions to prevent STDs.

There are many ways healthcare providers can provide culturally competent care for LGBTQ+ patients. Avoidance of unconscious and perceived biases and assumptions is the first step in decreasing the stigmatization felt by the community. Taking the time to learn terms commonly used by the LGBTQ+ community, what they mean, and asking how patients would like to be addressed creates a more inclusive environment. Continuous education for staff and providers to be comfortable discussing sexual and gender minority groups and the special needs for each population within the community can help make the patient feel their concerns are being heard and are valid. Above all, providing a caring, empathetic, and compassionate environment is needed to bring the best care to every patient.

References: <u>Cultural Competence in the Care of LGBTQ Patients</u>; <u>Health Care Disparities Among Lesbian, Gay, Bisex-ual, and Transgender Youth: A Literature Review</u>; <u>Cancer and lesbian, gay, bisexual, transgender/transsexual, and gueer/questioning (LGBTQ) populations</u>; <u>CDC Health Considerations for LGBTQ+ Youth</u>

# NATIONAL MOSQUITO CONTROL AWARENESS WEEK

Each June, the American Mosquito Control Association (AMCA) recognizes *National Mosquito Control Awareness Week*. This national week of observance, occurring this year from June 20 to June 26, serves to educate and remind the public on how to protect themselves from mosquitoes and the diseases they can carry. *National Mosquito Control Awareness Week* is also a time to reflect on the important services provided by mosquito control personnel at the local, state, and national levels.

Mosquito control plays a crucial role in protecting the public against mosquito-borne diseases, such as West Nile virus, eastern equine encephalitis, Zika virus, Chikungunya, dengue fever, and malaria. Mosquito control programs in Florida work closely with county health departments and other partners to perform a variety of activities, including animal surveillance (e.g., sentinel chicken and bird surveillance), source reduction (e.g., spraying for mosquitoes), and educating the public about personal protection against mosquitoes. Emergency room personnel, officials in neighboring counties, veterinarians, and communities also work closely with mosquito control programs in response to various levels of mosquito activity.

Health care providers also play an important role in the mosquito control response. Providers may share important preventive measures with their patients to reduce the risk of mosquito-borne disease transmission and perform laboratory testing if an illness is suspected. If a provider suspects that their patient meets the case definition for a mosquito-borne disease or is concerned of the potential for disease transmission, it is imperative that they contact the local county health department and report new cases of disease.

## SEMINOLE COUNTY MONTHLY SURVEILLANCE DATA

Confirmed and probable cases of select notifiable diseases as per 64D 3, Florida Administrative Code THESE DATA ARE PROVISIONAL AND SUBJECT TO CHANGE

DiseaseHay 2021May 2021SettingFloridal 2021202020182018A. Vaccina ProventableFFFFFFFNearlies00000000Marips000000000Pertuasi00001010101010Pertuasi0000401111S. CNS Dissase S. Bacterentis000 </th <th></th> <th colspan="2">Seminole Monthly Total</th> <th colspan="2">Year to Date Total</th> <th colspan="3">Seminole County Annual Totals</th>		Seminole Monthly Total		Year to Date Total		Seminole County Annual Totals		
A. Vacoin Processible NeedseImage	Disease	May 2021	May 2020	Seminole 2021	Florida 2021	2020	2019	2018
Meases000000000Partusais0003010Partusais410241084Vancola4100241084SchS biseaser & Bacterenias	A. Vaccine Preventable							
Mamps003010Patrusis000241064Varicelia4161241824178. CMS Disease GLDY000124182417Returtledis-Jacko Disease (CJDY)0002811123Meningize (Backrial, Cryptozocal, Mycole)0001000	Measles	0	0	0	0	0	0	0
Pertussis00241064A CNS Diseases & Bacteromias416124162417B. CNS Diseases & Bacteromias0004011Creut/elit-Jakob Disease (CJD)00002123Meningsoncal Disease0001000000C. Enteric Infections001141441Compoleaterionia0111174.441Coptopontionia0111174.441Coptopontionia0111174.411E col Shiga Toxin (*)01201596.679Glardinals0242341691418Hendysic Ureinis Syndrome (HUS)024359121111Sinonellosis001133140120121121Singellosis1011331344135134	Mumps	0	0	0	3	0	1	0
Varioelia416124124142417BCNS Disease Bacterman000029111Crutzfridri-Jacko Disease (GDD)0000291123Meningotes Disease000100	Pertussis	0	0	0	24	10	6	4
B. CMB Disease C. 200Image of the set of	Varicella	4	1	6	124	18	24	17
Creat/Field-Jacko Disease (CAD)000029123Meningtits (Bacerial, Cryptococal, Mycotic)00000000C. Entrat Infections0000000000C. Entrat Infections64111174411117<	B. CNS Diseases & Bacteremias							
Meningic Gaactrial, Cryptococcal, Mycotic)000101000Carmych Joesse00101000<	Creutzfeldt-Jakob Disease (CJD)	0	0	0	4	0	1	1
Maningcoccal Desase0000000C. Enteric Infactions64211505050Chyplopodidois0111714.44.1Chyplopodidois01201596.6251Chyplopodidois01201596.6251Chyplopodidois01201596.6251Chardiasi00242442441Chyplopodidois0001101010Giardiasis000130.000Istatosis000130.01212Singlobasi10110128122217Narl Hepatitis1011012810121212Narl Hepatitis101012221714141414Hepatitis A01012221314 </td <td>Meningitis (Bacterial, Cryptococcal, Mycotic)</td> <td>0</td> <td>0</td> <td>0</td> <td>29</td> <td>1</td> <td>2</td> <td>3</td>	Meningitis (Bacterial, Cryptococcal, Mycotic)	0	0	0	29	1	2	3
C. Enterl Infections   Image Notes   Image Notes </td <td>Meningococcal Disease</td> <td>0</td> <td>0</td> <td>0</td> <td>10</td> <td>0</td> <td>0</td> <td>0</td>	Meningococcal Disease	0	0	0	10	0	0	0
Campylobacteriosis6421136933.7559Cryptosporidiosis00056.251Cyclosporiasis00011201596.7.9Giardasis00002.10.0.0.0.0.Biardasis000013.0.	C. Enteric Infections							
Oryposponidosis   0   1   1   117   4   4   1     Cyclosponidosis   0   0   0   5   6   25   1     Cyclosponidosis   0   0   1   20   159   6   7   9     Gardiasia   0   2   4   234   16   14   18     Hemolytic Uremic Syndrome (HUS)   0   0   0   13   0.0   0   0     Saimonalcais   9   5   32   1453   6.9   120   121     Shigliois   1   0   1   0   128   10   48   30     Hapatitis A   0   1   0   120   13   14   49     Hepatitis A   0   1   0   128   10   48   30     Hapatitis A   0   1   0   122   8   16   16     Hepatitis A   0   1   10   12	Campylobacteriosis	6	4	21	1369	38	75	59
Op/dospontasis   O   O   1   20   15   6   25   1     E. odf Shiga Toxin (+)   O   1   20   159   6   7   9     Eardinalis   O   2   4   2324   116   114   18     Hemolytic Uremic Syndrome (HUS)   O   O   0   13   O   0   0     Salmonellosis   9   5   32   1453   59   120   121     Shigellosis   1   O   2   159   12   22   17     D. Viral Hepatitis   O   1   O   128   10   48   30     Hepatitis B. Acute   2   0   5   192   8   16   16     Hepatitis E. Acute   2   0   1   6   559   23   15   6     Evetoritome/Zonoses   0   1   6   3   0   1   14   14     Animal Rabies   0 <t< td=""><td>Cryptosporidiosis</td><td>0</td><td>1</td><td>1</td><td>117</td><td>4</td><td>4</td><td>1</td></t<>	Cryptosporidiosis	0	1	1	117	4	4	1
E col Shiga Toxin (+)   0   1   20   159   6   7   9     Giardiasis   0   2   4   234   16   14   18     Henolytic Uremic Syndrome (HUS)   0   0   0   13   0   0   0     Saltmonellosis   9   5   32   1453   59   120   121     Shigelosis   9   5   32   1453   59   120   121     Shigelosis   9   5   32   1453   59   120   121     Hepatitis B, Dregnant Women   1   0   1   120   2   13   4     Hepatitis B, Cuto   2   0   5   192   8   16   16     Hepatitis C, Acute   0   1   6   559   23   15   6     E. Vectorborne/Zonoses   0   3   0   31   7   2   1     Animal Rabies   00   0   0   0	Cyclosporiasis	0	0	0	5	6	25	1
Giardiasis024234161418Hemolytic Urenic Syndrome (HUS)000013000Salmonellosis0013000121121Shigellosis100128159120121Shigellosis1011991222217O. Viral HepattisHepattis B in Pregnant Women10110128104830Hepattis B, Acute01659231566E. Vectorborne/Zoonoses0165923156E. Vectorborne/Zoonoses41532131721Animal Rabies000001310134Chikungunya Fever00000110134Chikungunya Fever00000000Dengue0000000000Eastern Equine Encephaltis0000000000Kalvins Disease000000000119781978Charding121132767n/a*174519941978197819	E. coli Shiga Toxin (+)	0	1	20	159	6	7	9
Hemolylic Uremic Syndrome (HUS)   0   0   0   0   1   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0     Salmonellosis   9   5   32   1453   69   120   121   121     Shigalosis   1   0   2   159   122   22   177     Naral Hepatitis	Giardiasis	0	2	4	234	16	14	18
Listeriosis   0   0   13   0   0   13     Salmonellosis   9   5   32   1453   59   120   121     Shigellosis   1   0   2   159   12   22   17     Dyiral Hepattis	Hemolytic Uremic Syndrome (HUS)	0	0	0	2	0	0	0
Salmonellosis   9   5   32   1453   59   120   121     Shigelosis   1   0   2   159   12   22   17     D. Viral Hepattis   0   1   00   128   10   48   30     Hepattis B in Pregnant Women   1   0   1   120   2   13   4     Hepattis B, Acute   2   0   5   192   8   16   16     Hepattis C, Acute   0   1   6   559   23   15   6     E, VectorOme/Zoonese   0   1   6   59   23   13   4     Animal Rabies   0   3   0   31   7   2   1     Rabies, possible exposure   4   15   32   1301   135   180   134     Chikungunya Fever   0   0   0   1   0   0   1     Dengue   0   0   0   0	Listeriosis	0	0	0	13	0	0	0
Shigeliosis 1 0 2 159 12 22 17   D. Viral Hepatitis 0 1 0 128 10 48 30   Hepatitis Bin Pregnant Women 1 0 1 120 2 13 4   Hepatitis Bin Pregnant Women 1 0 1 120 2 13 4   Hepatitis Bin Pregnant Women 1 0 1 120 2 13 4   Hepatitis C, Acute 0 1 6 559 23 15 6   E. Vectorbornel/Zonoses 0 3 0 31 7 2 1   Rables, possible exposure 4 15 32 1301 135 180 134   Chikungunya Fever 0 0 0 0 0 0 0 0   Bastem Equine Encephalitis 0 0 0 0 0 0 0 0 0   Kabies, possible exposure 0 0 0 0 0 0 0 0	Salmonellosis	9	5	32	1453	59	120	121
D. Viral Hepatitis   Image: Constraint of the synthesis of the synthes of the synthilis (tate tatent; Neurosynthilis of the synthilis (tate	Shigellosis	1	0	2	159	12	22	17
Hepatitis A   0   1   0   128   10   48   30     Hepatitis B in Pregnant Women   1   0   1   120   2   13   4     Hepatitis B, Acute   2   0   5   192   8   16   16     Hepatitis C, Acute   0   1   6   559   23   15   6     E. Vactorborne/Zoonoses   0   3   0   31   7   2   1     Rabies, possible exposure   4   15   32   1301   135   180   134     Ohikungunya Fever   0   0   0   1   0   0   1     Dengue   0   0   0   0   0   0   0   0   1     Virung Equation   0 <td< td=""><td>D. Viral Hepatitis</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	D. Viral Hepatitis							
Hepatitis B in Pregnant Women   1   0   1   120   2   13   4     Hepatitis B, Acute   2   0   5   192   8   16   16     Hepatitis C, Acute   0   1   6   559   23   15   6     E. Vectorborne/Zoonoses   0   3   0   31   7   2   1     Animal Rables   0   3   0   31   7   2   1     Rables, possible exposure   4   15   32   1301   135   180   134     Chikungunya Fever   0   0   0   1   0   0   1     Dengue   0   0   0   0   0   0   0   0   0     Kikungunya Fever   0	Hepatitis A	0	1	0	128	10	48	30
Hepatitis B, Acute   2   0   5   192   8   16   16     Hepatitis C, Acute   0   1   6   559   23   15   6     E. Vactorborne/Zooneses   0   3   0   31   7   2   1     Animal Rables   0   3   0   31   7   2   1     Rables, possible exposure   4   15   32   1301   135   180   134     Chikungunya Fever   0   0   0   0   1   0   0   1     Dengue   0	Hepatitis B in Pregnant Women	1	0	1	120	2	13	4
Hepatitis C, Acute   0   1   6   559   23   15   6     E. Vectorborne/Zoonoses   0   3   0   31   7   2   1     Animal Rabies   0   3   0   31   7   2   1     Rabies, possible exposure   4   15   32   1301   135   180   134     Chikungunya Fever   0   0   0   1   0   0   1     Dengue   0   0   0   0   0   0   0   0   0     Eastern Equine Encephalitis   0 </td <td>Hepatitis B, Acute</td> <td>2</td> <td>0</td> <td>5</td> <td>192</td> <td>8</td> <td>16</td> <td>16</td>	Hepatitis B, Acute	2	0	5	192	8	16	16
E. Vectorborne/Zoonoses   Image: Constant of the second	Hepatitis C, Acute	0	1	6	559	23	15	6
Animal Rabies   0   3   0   31   7   2   1     Rabies, possible exposure   4   15   32   1301   135   180   134     Chikungunya Fever   0   0   0   1   0   0   1     Dengue   0   <	E. Vectorborne/Zoonoses							
Abies, possible exposure   4   15   32   1301   135   180   134     Chikungunya Fever   0   0   0   1   0   0   1   0   0   1     Dengue   0	Animal Rabies	0	3	0	31	7	2	1
Chikungunya Fever   0   0   0   1   0   0   1     Dengue   0	Rabies, possible exposure	4	15	32	1301	135	180	134
Dengue   0 <td>Chikungunya Fever</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>1</td>	Chikungunya Fever	0	0	0	1	0	0	1
Description   0 <th< td=""><td>Dengue</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>5</td><td>0</td></th<>	Dengue	0	0	0	0	0	5	0
Lyme Disease   0   0   0   41   3   4   3     Malaria   0   0   0   10   0   3   4     West Nile Virus   0   0   0   10   0   3   4     West Nile Virus   0 <td< td=""><td>Eastern Equine Encephalitis</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></td<>	Eastern Equine Encephalitis	0	0	0	0	0	0	0
Malaria   0   0   0   10   0   3   4     West Nile Virus   0   0   0   1   0	Lyme Disease	0	0	0	41	3	4	3
West Nile Virus   0   0   0   1   0   0   0     Zika Virus Disease   0   0   0   0   0   0   0   1     F. Others	Malaria	0	0	0	10	0	3	4
Zika Virus Disease   0   0   0   0   0   0   0   1     F. Others   Image: Chlamydia   121   132   767   n/a*   1745   1994   1978     Chlamydia   121   132   767   n/a*   1745   1994   1978     Gonorrhea   47   36   279   n/a*   592   619   646     Hansen's Disease   0   0   0   0   5   0   0   1     Legionellosis   2   0   4   167   133   8   16     Mercury Poisoning   0   0   0   6   0   0   0     Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Late Latent   0   3   29   n/a*   61   55   63     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32	West Nile Virus	0	0	0	1	0	0	0
F. Others   Image: Constraint of the second seco	Zika Virus Disease	0	0	0	0	0	0	1
Chlamydia   121   132   767   n/a*   1745   1994   1978     Gonorrhea   47   36   279   n/a*   592   619   646     Hansen's Disease   0   0   0   5   0   0   1     Legionellosis   2   0   4   167   13   8   16     Mercury Poisoning   0   0   0   6   0   0   0     Syphilis, Total   9   5   84   n/a*   151   149   132     Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0	F. Others							
Gonorrhea   47   36   279   n/a*   592   619   646     Hansen's Disease   0   0   0   5   0   0   1     Legionellosis   2   0   4   167   13   8   16     Mercury Poisoning   0   0   0   6   0   0   0     Syphilis, Total   9   5   84   n/a*   151   149   132     Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   1   0   55   5   2   2	Chlamydia	121	132	767	n/a*	1745	1994	1978
Hansen's Disease   0   0   0   5   0   0   1     Legionellosis   2   0   4   167   13   8   16     Mercury Poisoning   0   0   0   6   0   0   0     Syphilis, Total   9   5   84   n/a*   151   149   132     Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   0   27   n/a*   38   48   32     Tuberculosis   0   0   2   n/a*   0   0   0     Vibrio Infections   0   1   0   55   5   2   2	Gonorrhea	47	36	279	n/a*	592	619	646
Legionellosis   2   0   4   167   13   8   16     Mercury Poisoning   0   0   0   6   0	Hansen's Disease	0	0	0	5	0	0	1
Mercury Poisoning   0   0   0   6   0   0   0     Syphilis, Total   9   5   84   n/a*   151   149   132     Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   1   0   2   1/a*   0   0	Legionellosis	2	0	4	167	13	8	16
Syphilis, Total   9   5   84   n/a*   151   149   132     Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   1   0   55   5   2   2	Mercury Poisoning	0	0	0	6	0	0	0
Syphilis, Infectious (Primary and Secondary)   5   2   28   n/a*   51   46   35     Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   2   n/a*   0   0   0     Vibrio Infections   0   1   0   55   5   2   2	Syphilis, Total	9	5	84	n/a*	151	149	132
Syphilis, Early Latent   0   3   29   n/a*   61   55   63     Syphilis, Congenital   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   1   0   55   5   2   2	Syphilis, Infectious (Primary and Secondary)	5	2	28	n/a*	51	46	35
Syphilis, Congenital   0   0   0   0   n/a*   1   0   2     Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   1   0   55   5   2   2	Syphilis, Early Latent	0	3	29	n/a*	61	55	63
Syphilis, Late Syphilis (Late Latent; Neurosyphilis)   4   0   27   n/a*   38   48   32     Tuberculosis   0   0   2   n/a*   0   0   0     Vibrio Infections   0   1   0   55   5   2   2	Syphilis, Congenital	0	0	0	n/a*	1	0	2
Tuberculosis   0   0   2   n/a*   0   0   0     Vibrio Infections   0   1   0   55   5   2   2	Syphilis, Late Syphilis (Late Latent: Neurosyphilis)	4	0	27	n/a*	38	48	32
Vibrio Infections   0   1   0   55   5   2   2	Tuberculosis	0	0	2	n/a*	0	0	0
	Vibrio Infections	0	1	0	55	5	2	2

\*n/a—Data not available

# Florida Department of Health in Seminole County

400 W Airport Blvd, Sanford, FL 32773 Phone: 407-665-3000

**Donna Walsh, MPA, BSN, RN** Health Officer

**Ana Scuteri, MPH** Community & Population Health Director

Sarah Alvarez Wright, MPH, BSN Executive Community Health Nursing Director

**Dr. Meena Joseph, MD** Medical Director

Udgit Mehta, MBA, FCCM Business & Community Relations Director

#### Epi Scope Staff

**Kevin Baker, MPH, CPH, CHES** Epi Scope Editor Epidemiology Program Manager

Maria Bermudez, MS Carley Robinson, MPH, CPH Keisha Nauth, MPH Tara Rao, MS, MS Tyler Weston, MPH Taylor Kwiatkowski, MPH Epidemiology Program Staff & Contributors

#### **Disease Reporting**

**Epidemiology Program** COVID-19 Phone: 407-665-3000, option 1 Non-COVID-19 Phone: 407-665-3243 Fax: 407-845-6055

Afterhours Urgent Disease Reporting and Consultations Phone: 407-665-3000, option 1

**Tuberculosis Program** Phone: 407-665-3243 Fax: 407-665-3279

**STD Program** Phone: 407-665-3384 Fax: 407-845-6134

HIV/AIDS Program Phone: 407-723-5065

#### **Questions?**

**Email:** DiseaseControlSeminole@FLHealth.gov

# ADDITIONAL INFORMATION AND RESOURCES

(cont. from page 2—National Mosquito Control Awareness Week)

Mosquito control is a significant function of public health, and *National Mosquito Control Awareness Week* is a great time to get involved. For more information about mosquito-borne disease and mosquito control, as well as educational materials to post in your facility and share with patients, please visit Seminole County's <u>Mosquito Control Program</u> webpage, the Florida Department of Health's webpage on <u>Mosquito-borne Diseases</u>, and the Centers for Disease Control and Prevention's <u>Mosquito Control</u> webpage.

For any questions about mosquito-borne diseases or to report a suspected mosquito-borne disease, contact the Florida Department of Health in Seminole County (DOH-Seminole) Epidemiology Program at 407-665-3243.

Sources: <u>CDC Mosquito Control; EPA Mosquito Control; FDOH</u> <u>Mosquito-borne Diseases Guidebook; Mosquito.org</u>—Mosquito <u>Week; Seminole County, Florida: Mosquito Control</u>

## Influenza & Acute Respiratory Illness Surveillance

Heightened influenza surveillance has concluded for the 2020-2021 influenza season. For statewide and nationwide influenza surveillance reports, please visit the Florida Department of Health and CDC websites below:

Florida Statewide Weekly Influenza Surveillance Report—Flu Review CDC U.S. Weekly Influenza Surveillance Report—FluView

### Practitioner Resources

Florida Department of Health Practitioner Disease Report Form Florida COVID-19 Data and Information

### Health Alerts and Advisories

- <u>CDC Travel Health Notices</u>
- FDA Food Recalls

### Epi Scope Information

The Epi Scope is a monthly newsletter provided at no cost to consumers to share epidemiological data and trends, public health and health care guidance and current events to Seminole County stakeholders.



To subscribe to the Epi Scope distribution list, please visit the Florida Department of Health in Seminole County <u>Epi Scope webpage</u>. 4